MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Progressive supranuclear palsy(PSP)"

  • 2025 International Congress

    Neuropsychiatric profile of progressive supranuclear palsy phenotypes

    V. Martinez-Villota, L. Ortega-Bolaños, M. Rodríguez-Violante (Pasto, Colombia)

    Objective: To analyze neuropsychiatric symptoms among phenotypes of patients with Progressive supranuclear palsy  (PSP) in movement disorder centers in Colombia and Mexico. Background: Progressive supranuclear…
  • 2025 International Congress

    4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies and CBD from PSP in post-mortem brain samples

    L. de Mena, M. Fernandez, J. Perez, C. Painous, A. Camara, A. Perez-Soriano, L. Molina-Porcel, E. Artikis, B. Caughey, Y. Compta (Barcelona, Spain)

    Objective: To investigate whether 4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies as well as CBD from PSP in post-mortem brain samples. Background: 4 repeat…
  • 2025 International Congress

    Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study

    R. Cilia, V. Leta, F. Colucci, A. Suppa, F. Valentino, C. Terranova, C. Leuzzi, J. Cordasco, R. Telese, A. Braccia, G. Gaudiano, A. Elia, A. Zampogna, G. Pinola, M. Patera, G. Belluscio, S. Crivellari, E. Antoniazzi, S. Cascino, A. Giaco, A. Masaracchio, C. Moreschi, M. Catotti, R. Eleopra (Messina, Italy)

    Objective: To evaluate the effectiveness of a telemedicine-based (‘Telenursing’) home healthcare model, coordinated by a Parkinsonism Nurse Specialist (PKNS), in improving the quality of life…
  • 2025 International Congress

    An Interesting Case of Oculo-Palatal-Pharyngeal Tremor

    R. Robinson, A. Oswal, MT. Hu (Oxford, United Kingdom)

    Objective: We present a case report of a 59 year old with a diagnosis of clinically possible progressive supranuclear palsy (PSP) and clinical finding of…
  • 2025 International Congress

    Neuroinflammatory response is determined by HLA genotype in progressive supranuclear palsy

    G. Kovacs, H. Chasiotis, S. Zaheer, J. Wang, J. Li, MC. Tartaglia, S. Fox, A. Lang, S. Forrest (Toronto, Canada)

    Objective: Our aim was to examine whether the HLA haplotypes influence the neuroinflammatory response in a cohort of neuropathologically diagnosed PSP cases. Background: Progressive supranuclear…
  • 2025 International Congress

    Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS)

    R. Durcan, H. Paula, D. Street, A. Murley, S. Jones, A. Church, C. Kobylecki, V. Marshall, C. Antoniades, B. Ghosh, J. Rowe (Cambridge, United Kingdom)

    Objective: The NORAPS phase II study (ISRCTN99462035) investigates the safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a neurodegenerative…
  • 2025 International Congress

    Validation of the Short Progressive Supranuclear Palsy Quality of Life Scale in PSPNI

    Q. Shen, XY. Li, J. Wang, FT. Liu (Shanghai, China)

    Objective: This study aimed to evaluate the reliability, validity, and sensitivity to change of the PSP-ShoQoL in PSPNI, a longitudinal Chinese PSP cohort. Background: Self-reported…
  • 2025 International Congress

    Quantitative Regional Tau Pathology and Spatial Transcriptomics Identify Signatures of Phenotypic Diversity in Progressive Supranuclear Palsy.

    P. Cullinane, J. Parmera, T. Curless, L. Paras Chajed, S. Wrigley, W. Sifontes Valladares, J. Anton Arnal, M. Burrows, K. Ebanks, M. Blunskyte, D. Gavriouchkina, L. Binding, T. Revesz, S. Brandner, A. Young, E. de Pablo-Fernández, H. Morris, Y. Lim, H. Nelvagal, T. Warner, Z. Jaunmuktane (London, United Kingdom)

    Objective: To determine the pathological and molecular determinants of phenotypic diversity in PSP. Background: PSP exhibits broad variability in clinical phenotype and progression, however the…
  • 2025 International Congress

    Utilizing the 15-item modification of the PSPRS rating scale (mPSPRS-15) as the primary endpoint for future clinical trials in progressive supranuclear palsy

    F. Nery, T. Nevmyrych, J. Murphy, S. Wu, Y. Zabar, A. Gafson, S. Bullain, J. O’Gorman (Cambridge, USA)

    Objective: To compare the properties of PSPRS-28, mPSPRS-15, and the rPSPRS-10 and assess their utility as a primary endpoint in PSP trials. Background: Progressive supranuclear…
  • 2025 International Congress

    Concomitant Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis Versus Motoneuron Phenotype of PSP in Ukrainian Patient

    Y. Trufanov, Y. Compta, M. Trishchynska, N. Khanenko, G. Chupryna, V. Sereda, A. Ovchynnykova (Kyiv, Ukraine)

    Objective: To provide a description of a rare case of mixed progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS) in Ukrainian patient. Background: The…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 49
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley